Double‐blind, randomised, placebo‐controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease
2020 ◽
2020 ◽
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
Keyword(s):